Thermo Fisher Scientific Inc. (NYSE:TMO) on Wednesday reported third-quarter adjusted earnings of $6.68 per share, beating the street view of $6.40.
The life science giant’s quarterly sales of $12.137 billion increased 9% year-over-year, beating the analyst consensus estimate of $11.946 billion. Organic revenue growth was 6%.
Adjusted operating margin was 24.5%, compared with 23.3% a year ago.
Raised Fiscal 2026 Guidance And Market Demand
Thermo Fisher Scientific raised fiscal 2026 adjusted earnings guidance from $24.93-$25.33 per share to $25.13-$25.43 per share, compared to the consensus of $25.14.
Read Also: Thermo Fisher Says India Is One Of Its Fastest-Growing Markets
The company also raised 2026 sales guidance from $47.4 billion-$48.10 billion to $47.70 billion-$48.20 billion vs $47.885 billion.
The company in its earnings call said that the improved end market conditions witnessed in the second quarter continued in the third quarter with strong customer activity.
Segment Breakdown
In Life Sciences Solutions, Q3 reported revenue increased 5% to $2.719 billion versus the prior-year quarter, and organic revenue growth was 1%. Growth in this segment was led by the bioproduction business.
During the quarter, in the Analytical Instruments segment, both reported revenue and organic revenue increased 6% to $2.00 billion, led by growth in the electron microscopy business, and there was also good growth in the chromatography and mass spectrometry business.
Specialty Diagnostics, in Q3, reported revenue declined 6% year over year to $1.098 billion and organic revenue was flat. Growth in this segment was led by our transplant diagnostics business.
In the Laboratory Products and Biopharma Services segment, reported revenue increased 15% to $6.863 billion, and organic revenue growth was 10%.
In Q3, the company said it delivered strong growth in the pharma services business, in the research and safety market channel, and also had strong growth in the clinical research business.
End Market Performance And Executive Insights
Chairman and CEO Marc Casper said the pharma and biotech business delivered high-single-digit growth during the quarter, led by the pharma services business and the research and safety market channel.
The company also reported growth in the clinical research business.
In academic and government, revenue was flat during the quarter; it saw good performance in the chromatography and mass spectrometry business.
TMO Price Action: Thermo Fisher Scientific shares were up 1.04% at $694.55 at the time of publication on Wednesday. The stock is trading near its 52-week high of $704.00, according to Benzinga Pro data.
Read Also: Ripple Urges SEC Not to Classify Tokens as Securities Indefinitely
Photo: Shutterstock